ウォックハートは12年の開発期間を経て、同社の新規抗生物質Zaynichの米国食品医薬品局（USFDA）による承認を取得しました。本剤は多剤耐性菌を標的としており、ピーク時の売上高は15億ドルに達すると予測されています。この承認を受けて投資家心理が改善し、同社の株価は上昇しました。
今回の承認は、近年純損失を計上してきたウォックハートにとって転換点となる可能性があります。Zaynichは既存の治療薬に耐性を持つ感染症に対処するために開発されたものであり、新たな抗生物質を求める医薬品市場の需要を満たすものとなります。
AIによるレポート AIによって生成された画像 事実確認済み
Researchers at the University of Kent, working with University College London, report that madecassic acid—a compound derived from the medicinal herb Centella asiatica and widely used in skincare—can inhibit the growth of antibiotic-resistant E. coli by targeting a bacterial respiratory system not found in humans or other animals.
British surgeon Ara Darzi told the WIRED Health conference that artificial intelligence is set to revolutionize the diagnosis and treatment of drug-resistant infections. He cautioned that insufficient incentives might block these innovations from reaching patients. Antibiotic resistance already causes over a million deaths worldwide each year.
AIによるレポート
Gland Pharma shares reached a new 52-week high after the company reported strong results for the March quarter and full year. The European unit Cenexi showed signs of recovery while new product launches and capacity additions supported the outlook.
Indian fund managers directed fresh investments into pharmaceutical and non-banking financial companies during April. The moves targeted defensive stocks amid concerns over oil prices and tensions in West Asia.
AIによるレポート
Egypt’s Ministry of Health has held talks with a US pharmaceutical company to discuss investment in healthcare and drug manufacturing. The meeting aims to attract foreign capital and boost local production capacity.